Published in Mod Pathol on November 24, 2006
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol (2013) 1.62
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer (2009) 1.43
Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int (2014) 1.21
Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer (2009) 1.19
ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res (2008) 1.17
Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models. J Transl Med (2012) 1.11
HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology (2011) 1.10
Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas. Clin Cancer Res (2012) 1.07
Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int (2010) 1.05
Targeted endoscopic imaging. Gastrointest Endosc Clin N Am (2009) 1.03
HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol (2011) 1.01
Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol (2013) 0.99
Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. Sci Rep (2016) 0.97
Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction. Cancer Biol Ther (2013) 0.96
Esophageal adenocarcinoma arising in Barrett esophagus. Cancer Lett (2008) 0.96
Early G₁ cyclin-dependent kinases as prognostic markers and potential therapeutic targets in esophageal adenocarcinoma. Clin Cancer Res (2011) 0.94
Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer. PLoS One (2012) 0.93
A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage. Ann Oncol (2014) 0.92
ALCAM (CD166) expression and serum levels in pancreatic cancer. PLoS One (2012) 0.89
The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples. Transl Oncol (2013) 0.88
HER2 amplification in gastroesophageal adenocarcinoma: correlation of two antibodies using gastric cancer scoring criteria, H score, and digital image analysis with fluorescence in situ hybridization. Am J Clin Pathol (2012) 0.88
Are biopsy specimens predictive of HER2 status in gastric cancer patients? Dig Dis Sci (2012) 0.88
Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma. Cancer Res (2012) 0.87
Validation of tissue microarray technology in squamous cell carcinoma of the esophagus. Virchows Arch (2008) 0.86
Esophageal adenocarcinoma: treatment modalities in the era of targeted therapy. Dig Dis Sci (2010) 0.85
Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. Oncotarget (2015) 0.85
CXCR7 expression in esophageal cancer. J Transl Med (2013) 0.83
Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology. World J Gastroenterol (2012) 0.83
Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers. Oncologist (2010) 0.83
Genetic diagnosis of patients with esophageal cancer using FISH. Oncol Lett (2010) 0.82
Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma. Oncol Lett (2015) 0.82
Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma. Br J Cancer (2015) 0.81
HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis. J Gastrointest Oncol (2014) 0.81
HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. J Cancer Res Clin Oncol (2014) 0.80
HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma. Oncol Lett (2013) 0.80
FGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal Carcinoma. PLoS One (2015) 0.80
Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma. BMC Cancer (2011) 0.80
Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery. PLoS One (2010) 0.79
Anti-ERBB2 sh-RNA suppress both cell growth and tumor growth in ERBB2-overexpressing upper gastrointestinal adenocarcinomas. J Gastrointest Surg (2009) 0.79
Characterization of a novel tumorigenic esophageal adenocarcinoma cell line: OANC1. Dig Dis Sci (2014) 0.79
C-Met as a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome. J Cancer (2016) 0.77
Discordant HER2 expression and response to neoadjuvant chemoradiotherapy in esophagogastric adenocarcinoma. J Gastrointest Oncol (2016) 0.77
Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib. Langenbecks Arch Surg (2014) 0.77
Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer. ISRN Surg (2012) 0.76
HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practice. World J Gastroenterol (2016) 0.75
Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study. World J Gastroenterol (2012) 0.75
Expression levels of HER2 and MRP1 are not prognostic factors of long-term survival in 829 patients with esophageal squamous cell carcinoma. Oncol Lett (2015) 0.75
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med (2011) 12.52
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA (2010) 6.65
Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery (2007) 6.62
Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res (2002) 5.99
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer. Nat Genet (2007) 5.19
Frequent EpCam protein expression in human carcinomas. Hum Pathol (2004) 4.94
Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery (2007) 4.72
Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. J Hepatol (2012) 4.04
FOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency. J Hepatol (2012) 3.57
Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol (2004) 3.49
HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol (2009) 3.37
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet (2002) 3.32
Virtual autopsy as an alternative to traditional medical autopsy in the intensive care unit: a prospective cohort study. Ann Intern Med (2012) 3.29
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell (2013) 3.08
Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell (2008) 3.01
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res (2005) 2.85
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
Downsides of robot-assisted laparoscopic radical prostatectomy: limitations and complications. Eur Urol (2009) 2.76
Prevalence of a tertiary Gleason grade and its impact on adverse histopathologic parameters in a contemporary radical prostatectomy series. Eur Urol (2008) 2.72
Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene (2003) 2.71
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol (2014) 2.64
En bloc vascular resection for locally advanced pancreatic malignancies infiltrating major blood vessels: perioperative outcome and long-term survival in 136 patients. Ann Surg (2008) 2.64
SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. J Clin Invest (2011) 2.60
Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res (2004) 2.55
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol (2010) 2.48
POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res (2003) 2.45
Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat Genet (2004) 2.44
Marked gene transcript level alterations occur early during radical prostatectomy. Eur Urol (2007) 2.41
Prevalence of KIT expression in human tumors. J Clin Oncol (2004) 2.40
Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol (2008) 2.32
Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol (2004) 2.32
Changes in cytoskeletal protein composition indicative of an epithelial-mesenchymal transition in human micrometastatic and primary breast carcinoma cells. Clin Cancer Res (2005) 2.31
Postpancreatectomy hemorrhage: diagnosis and treatment: an analysis in 1669 consecutive pancreatic resections. Ann Surg (2007) 2.29
High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat (2004) 2.14
Options and limitations in applying the fistula classification by the International Study Group for Pancreatic Fistula. Ann Surg (2012) 2.13
The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat (2005) 2.10
Preoperative Pancreatic Resection (PREPARE) score: a prospective multicenter-based morbidity risk score. Ann Surg (2014) 2.09
Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. Genes Chromosomes Cancer (2002) 2.04
Signal transducer and activator of transcription-5 activation and breast cancer prognosis. J Clin Oncol (2004) 2.04
Rhinosinusitis: Establishing definitions for clinical research and patient care. Otolaryngol Head Neck Surg (2004) 2.01
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int J Oncol (2004) 1.95
DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol (2006) 1.80
Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. Am J Pathol (2012) 1.80
Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol (2011) 1.77
ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res (2011) 1.75
Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology (2007) 1.75
Resection vs drainage in treatment of chronic pancreatitis: long-term results of a randomized trial. Gastroenterology (2008) 1.75
Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol (2004) 1.75
High incidence of EMMPRIN expression in human tumors. Int J Cancer (2006) 1.74
Quantitative analysis of the binding affinity of poly(ADP-ribose) to specific binding proteins as a function of chain length. Nucleic Acids Res (2007) 1.73
Arterial neovascularization and inflammation in vulnerable patients: early and late signs of symptomatic atherosclerosis. Circulation (2004) 1.68
SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res (2006) 1.66
Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells. Hepatology (2011) 1.65
AMACR expression in colorectal cancer is associated with left-sided tumor localization. Virchows Arch (2008) 1.61
Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst (2005) 1.60
Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol (2002) 1.59
Molecular cancer phenotype in normal prostate tissue. Eur Urol (2008) 1.58
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. Blood (2004) 1.55
Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer (2005) 1.55
Heterogeneity of epidermal growth factor receptor status and mutations of KRAS/PIK3CA in circulating tumor cells of patients with colorectal cancer. Clin Chem (2012) 1.53
Impaired gastric acidification negatively affects calcium homeostasis and bone mass. Nat Med (2009) 1.52
The impact of early goal-directed fluid management on survival in an experimental model of severe acute pancreatitis. Intensive Care Med (2013) 1.51
Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol (2008) 1.51
Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Res (2003) 1.51
Tumor volume in insignificant prostate cancer: increasing threshold gains increasing risk. Prostate (2014) 1.50
Effectiveness of radical en-bloc-esophagectomy compared to transhiatal esophagectomy in squamous cell cancer of the esophagus is influenced by nodal micrometastases. J Surg Oncol (2006) 1.50
Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol Cancer Res (2007) 1.49
Glasgow Prognostic Score is a predictor of perioperative and long-term outcome in patients with only surgically treated esophageal cancer. Ann Surg Oncol (2010) 1.49
VHL mutations and their correlation with tumour cell proliferation, microvessel density, and patient prognosis in clear cell renal cell carcinoma. J Pathol (2002) 1.48